Європейський Союз - мальтійська - EMA (European Medicines Agency)

novo nordisk a/s - insulin human - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus.

Європейський Союз - мальтійська - EMA (European Medicines Agency)

novo nordisk a/s - insulin human - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus.

Європейський Союз - мальтійська - EMA (European Medicines Agency)

novo nordisk a/s - insulina aspart, l-insulina degludec - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus f'adulti, adolexxenti u tfal mill-età ta 'sentejn.

Європейський Союз - мальтійська - EMA (European Medicines Agency)

novo nordisk a/s - insulina degludec - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus fl-adulti.

Європейський Союз - мальтійська - EMA (European Medicines Agency)

novo nordisk a/s - insulin human - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus.

Європейський Союз - мальтійська - EMA (European Medicines Agency)

novo nordisk a/s - insulin human - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus.

Європейський Союз - мальтійська - EMA (European Medicines Agency)

novo nordisk a/s - insulin aspart - diabetes mellitus - drugs used in diabetes, insulins and analogues for injection, fast-acting - trattament tad-dijabete mellitus f'adulti, adolexxenti u tfal ta 'sena u aktar.

Європейський Союз - мальтійська - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - diabetes mellitus, tip 2 - drogi użati fid-dijabete - rybelsus huwa indikat għall-kura ta 'adulti li mhumiex ikkontrollati biżżejjed b'dijabete mellitus tip 2 sabiex ittejjeb il-kontroll gliċemiku bħala żieda mad-dieta u l-exerciseas monoterapija b'metformin meta jitqies mhux xieraq minħabba l-intolleranza jew contraindicationsin flimkien ma' prodotti mediċinali oħra għall-kura tad-dijabete. għall-riżultati tal-istudju fir-rigward tal-kombinazzjonijiet, l-effetti fuq il-kontroll gliċemiku u episodji kardjovaskulari, u l-popolazzjonijiet studjati, ara sezzjonijiet 4. 4, 4. 5 u 5.

Європейський Союз - мальтійська - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunosoppressanti - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) huwa indikat għall-kura ta ' pazjenti adulti li ma kienux ikkurati qabel mjeloma multipla li mhumiex eliġibbli għal trapjant tal -. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) huwa indikat għall-kura ta ' pazjenti adulti li ma kienux ikkurati qabel mjeloma multipla li mhumiex eliġibbli għal trapjant tal -. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Європейський Союз - мальтійська - EMA (European Medicines Agency)

novo nordisk a/s - liraglutide - obesity; overweight - drogi użati fid-dijabete - saxenda huwa indikat bħala żieda mad-mnaqqsa dieta ta 'kaloriji u żieda fl-attività fiżika għall-ġestjoni tal-piż f'pazjenti adulti b'inizjali indiċi tal-massa tal-Ġisem (bmi) tal• ≥ 30 kg/m2 (obeżi), jew• ≥ 27 kg/m2 sa < 30 kg/m2 (piż żejjed) fil-preżenza ta' mill-inqas wieħed mill-piż relatata mal-ko-morbidità bħal dysglycaemia (pre-dijabete jew dijabete mellitus tip 2), pressjoni għolja, dislipidemija jew apnea waqt l-irqad. it-trattament b'saxenda għandu jitwaqqaf wara 12-il ġimgħa fuq l-3. 0 mg/kuljum-doża jekk il-pazjenti ma jkunux tilfu tal-inqas 5% tal-inizjali tagħhom piż tal-ġisem.